To some extent, the significant decrease in fasting plasma glucose in our cohort after treatment of hyperthyroidism (108.0 ± 19.6 to 91.2 ± 8.4 mg/dL, p < 0.001) might also reflect the alteration of serum hepassocin levels. Here, FGL1 is linked to hyperthyroidism.